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Recommended by Donna-Marie McCaﬀerty
Crohn’s disease (CD) is a multifactorial chronic inﬂammatory bowel disease of unknown cause. The aim of the present study was
toexploreifmRNAover-expressionofSSTR5andCCR7foundinCDpatientscouldbecorrelatedtorespectiveproteinexpression.
Whencomparedtohealthydonors,SSTR5wasover-expressed417 ±71timesinCDperipheralbloodmononuclearcells(PBMCs).
Flow cytometry experiments showed no correlation between mRNA and protein expression for SSTR5 in PBMCs. In an attempt
to ﬁnd a reason of such a high mRNA expression, SSTR5 present on CD PBMCs were tested and found as biologically active as
on healthy cells. In biopsies of CD intestinal tissue, SSTR5 was not over-expressed but CCR7, unchanged in PBMCs, was over-
expressed by 10 ± 3 times in the lamina propria. Confocal microscopy showed a good correlation of CCR7 mRNA and protein
expression in CD intestinal biopsies. Our data emphasize ﬂow and image cytometry as impossible to circumvent in complement
to molecular biology so to avoid false interpretation on receptor expressions. Once conﬁrmed by further large-scale studies, our
preliminary results suggest a role for SSTR5 and CCR7 in CD pathogenesis.
Copyright © 2009 Nathalie Taquet et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
AttemptstocorrelateproteinabundancewithmRNAexpres-
sion levels have had variable success. Three main reasons
have been suggested for the poor correlations between
mRNA and protein levels generally reported in the literature
[1]. First, there are many posttranscriptional mechanisms
involved in turning mRNA into proteins: a number of
complex steps between transcription and translation occur.
Second,proteinsmaydiﬀersubstantiallyintheirinvivohalf-
lives:thecellcancontroltheratesofdegradation orsynthesis
for a given protein, and there is signiﬁcant heterogeneity
even within proteins that have similar functions. Third, there
is a signiﬁcant amount of error and background noise in
both protein and mRNA experiments that limit our ability
to get a clear picture. The soundest way to follow protein
expression is the use of an antibody able to tag speciﬁcally
the desired epitop. This is applied generally in western blot
but can be more rapidly revealed by cytometry (image or
ﬂow). To test the pertinence of confocal microscopy and
ﬂow cytometry, we used these two techniques to determine
protein abundance of somatostatin receptor 5 (SSTR5) and
chemokine receptor CCR7, two receptors that we have found
tobesigniﬁcantlyincreasedinCrohn’sdisease(CD)patients’
peripheral blood mononuclear cells (PBMCs) and inﬂamed
intestinal mucosa, respectively (ongoing work, full data
not published). Crohn’s disease is a chronic inﬂammatory
bowel disease, which can aﬀect the whole gut, but is2 Mediators of Inﬂammation
more often located to the distal part of the small intestine
(ileum) and/or to the colon. Current pathogenic hypotheses
suggest that CD results from an aberrant immune response
towards (a) bacteria(s) from the gut ﬂora, in genetically
susceptible hosts [2, 3]. Nevertheless, and despite numerous
works examining speciﬁc potential pathogenic pathways or
analyzingpan-genome modiﬁcations inCD whichhave been
performed, results are often disappointing and sometimes
contradictoryornotreproduciblefromonestudytoanother.
This probably depends both on patient populations het-
erogeneity and variability, and on the methodological and
technical approach used. Therefore, identifying the most
reliable biochemical and/or biological techniques to study
the fundamental features of CD appears to be a preliminary
work of outstanding importance.
The aim of the present study was to explore if the
diﬀerential mRNA expression of SSTR5, we observed in
PBMCs from CD patients, and that of CCR7 in CD patients
biopsies,couldbecorrelatedtoproteinexpressionmonitored
by ﬂow or image cytometry.
2.MaterialsandMethods
2.1. Crohn’s Disease Patients. Ten patients aged 28 (median,
range: 20–42; 6 women, 4 men) presenting colonic (n = 4)
or ileocolonic (n = 6) disease participated to the study. At
the time tissue samples (blood or intestinal mucosa) were
collected, their disease was inactive (assessed by the Harvey
Bradshaw index; <4 for all patients) for more than 3 months
(median: 8, range: 3–27). No patient exhibited clinical signs
of infection and C-reactive protein concentration measured
routinely was normal (<5mg/L) in all patients. Finally,
stool culture, performed systematically, was negative for the
whole group. Two patients were treated on the long term by
inﬂiximab, 3 patients by azathioprine, one by methotrexate,
allonstabledosesformorethan3months.Fourpatientshad
no medication. Paired healthy age and sex-matched donors
were chosen for comparison. This work was approved by
the ethic committee (Comit´ e de Protection des Personnes
Nord-Ouest II, Amiens, France), and carried out according
to national guidelines.
2.2. Isolation of PBMCs and Tissue Collection. Peripheral
blood mononuclear cells were obtained through venopunc-
ture, in the morning, from overnight fasting patients or
healthyunpaidcontrolvolunteers.Cellswereseparatedusing
Ficoll-Histopaque density 1.077 gradient centrifugation as
previously described [4]. They were activated or not by
lipopolysaccharide from Salmonella abortus equi (LPS :
1μg/mL sterile water; Sigma Chemical 100mg, Salmonella
serotype 0128:B12) for 2 hours 30 minutes at 37
◦C. Then,
PBMCs were centrifuged, the pellet frozen in liquid nitrogen
and kept at −80
◦C. Cell culture supernatants were frozen for
cytokine determination.
Healthy control mucosal biopsies were obtained in
patients undergoing colonoscopy for colorectal cancer
screening (for family history of colorectal cancer; with
no clinical symptoms or biological abnormalities) showing
normal colonoscopy. In CD patients, biopsies were obtained
during colonoscopy performed to assess disease extent,
severity, and/or progression.
As a m p l eo fe a c ht i s s u es p e c i m e nw a su s e df o r
histopathologicalstudies,andsamplesfromthesamecolonic
area were frozen on D solution [5]a n ds t o r e da t−80
◦C.
In CD patients, biopsies have been performed in inﬂamed
mucosa.
2.3. RNA Extraction. Tissues were defrosted 15 minutes
on ice [5]. The cells were broken with a sterile piston
in phenol saturated 2M sodium acetate (pH 4.0) and
chloroform/isoamylic alcohol (49 : 1). After vortexing, the
lysates were incubated 15 minutes on ice then centrifuged for
20 minutes at 12000g (4◦C). Aqueous phase containing the
RNA was saved and the RNA precipitated by isopropanol for
one hour at −20
◦C. The RNA extract was centrifuged during
20 minutes 12000g (4◦C), and washed with 500μL of 70%
ethanol, then centrifuged 5 minutes at 12000g (4◦C) and
washed again with 75% ethanol. The RNA extract was dried
i naS p e e dV a ca n dr e s u s p e n d e di ns t e r i l ew a t e r .
The Tri Reagent (Molecular Research Center, Inc.,
Cincinnati, Ohio, USA) was used to isolate RNA from
PBMCs (5 · 106 cells) according to manufacturer’s instruc-
tions. Total mRNA was checked for integrity and con-
centration by means of the RNA 6000 LabChip kit on
an Agilent 2100 bioanalyzer: ratios of 28S RNA/18S RNA
had to be above 1.6 to validate a sample. Purity was
obtained by reading the absorbance at 260 and 280nm
ratio (A260/A280) between 1.8 and 2.0 to validate a sample.
The RNA Integrity Number (RIN) for assigning integrity
values to RNA measurements, was evaluated for each sample
according to Schroeder et al. [6].
2.4. Real-Time RT-PCR and PCR. Fiveμgo ft o t a lR N A
is reverse transcribed to single-stranded cDNA using the
High-Capacity cDNA Archive Kit. The RNA is preincubated
at 25
◦C for 10 minutes, followed by 2 hours at 37
◦C,
according to the manufacturer’s recommendations (Applied
Biosystems, Foster City, California, USA). Subsequently,
cDNA was kept at −20
◦C until used. In a 96 wells plate
(MicroAmp Optical 96-well Reaction, Applied Biosystems),
an aliquot of cDNA (100ng/μL) was mixed carefully in Taq-
Man Universal PCR Master Mix, DEPC water (Euromedex,
Souﬀelweyersheim, France) and TaqMan Predeveloped assay
reagents (PDAR Applied Biosystems, Foster City, California,
USA) then brieﬂy spun (15 seconds, 2000g). The 96 wells
plates were immediately sealed with an optical adhesive
cover, and centrifuged twice in a Sigma centrifuge for 1
minute at 2000g. Real-time RT-PCR has been performed
using an ABI Prism 7000 (Applied Biosystems, Foster City,
California, USA). Thermal cycling was carried out for 2
minutes at 50
◦C (to activate Uralic-DNA glycosylase), 10
minutes at 95
◦C (to inactivate Uralic-DNA glycosylase and
activate polymerase DNA AmpliTaq Gold), and 40 cycles of
15 seconds at 95
◦C, then 1 minute at 60
◦C. Each reaction
contained cDNA derived from around 1.5ng of total RNA.
The primer sequences and probes from the TaqMan HumanMediators of Inﬂammation 3
GPCR Panel (P/N 4367785 from Applied Biosystems) are
catalog no. Hs00265647 s1 for SSTR5 and Hs00171054 m1
for CCR7, respectively.
2.5. DNA Sequencing. After mRNA extraction, 100pg of
mRNA was added to 10mM dNTP Mix, 2 pmoles/mL of the
primers RT1 and RT2 (Operon, K¨ oln, Germany), and sterile
water. The mixture was incubated to 65
◦Cf o r5m i n u t e s ,
and kept on ice. The content of the tube was collected by
brief centrifugation (1000g). The 5x First Buﬀer, DTT 0.1M,
Recombinase Rnase Inhibitor and the SuperScript III RT
(kit In Vitrogen, Cergy Pontoise, France) were then added.
The tube was incubated for 5 minutes at 25
◦C, 60 minutes
at 50
◦C, and 15 minutes at 70
◦C (PTC-100 Programmable
ThermalController,MJResearchINC,Peltier-EﬀectCycling,
USA).
For one PCR tube reaction, 10x PCR Buﬀer (200mM
Tris-HCl pH 8.4, 500mM KCl), MgCl2 50mM, dNTP Mix
10mM, ampliﬁcation primers PCR1 and PCR2 10mM
(Operon, Cologne, Germany), Taq DNA polymerase 5U/mL
(Phusion High Fidelity DNA Polymerase, Finnzymes, Espoo,
Finland),cDNAfromﬁrst-strandreactionanddistilledwater
were mixed. The tube reaction has been put in incubation
at 98
◦C for 30 seconds to be denatured, and during 30
cycles of 10 seconds at 98
◦C, for 20 seconds at 75
◦C, and
f o r1m i n u t ea t7 2
◦C, and ﬁnish the program at 72
◦C
during 10 minutes. DNA and SmartLadder (Eurogentec,
Seraing, Belgium) were deposed in an agarose gel 1% in TAE
0.5x.
Total cDNA was checked for integrity and concentration
using the DNA 7500 LabChip kit on the Agilent 2100
bioanalyzer. It was also checked for purity by reading
absorbance at 260 and 280nm: ratios A260/A280 always
between 1.8 and 2.0.
2.6. Immunoﬂuorescence Staining on the Tissue ParaﬃnS e c -
tions. Tissue paraﬃn sections were placed at 57
◦C during 15
minutes and deparaﬃnised according a protocol previously
described by Kumada et al. [7]. Human tissue sections were
stainedovernightat4◦Cwiththeprimaryrabbitmonoclonal
antibody to CCR7 1 : 250 (Abcam, Paris, France) or rabbit
polyclonal to SSTR5 1 : 5000 (Ozyme, St Quentin en
Yvelines, France) in incubation Buﬀer (0.5% BSA-TBS pH
9.0). After three passages (10 minutes) in washing buﬀer
(0.1% BSA-TBS pH 9.0), sections were incubated for two
hours in presence of the secondary goat anti-rabbit Alexa
Fluor 647 antibody (In Vitrogen, Cergy Pontoise, France) in
incubation buﬀer. Finally, they were washed for 10 minutes
in Washing Buﬀer, then three times in TBS pH 9.0, and six
times under running water.
2.7. Acquisition and Images Analyzes. Image acquisition was
performed using a confocal microscope Leica SP5 (LEICA,
Mannheim, Germany). The software LAS AF (Leica) has
been used for the acquisition and the numerical recording of
the images, and its analysis has been carried out with Image J
(a freeware by Wayne Rasband, National Institutes of Health,
USA).
2.8. Flow Cytometry. Fixation and permeabilisation were
performed thanks to the cytoﬁx/cytoperm kit (BD Bio-
sciences, Le Pont de Claix, France) and incubated one hour
with a primary rabbit polyclonal antibody to SSTR5 1 :
5000 (Ozyme, St Quentin en Yvelines, France) in incubation
buﬀer or with isotypic antibodies for all controls. After three
washes in Perm/Wash, cells were incubated one hour with
the Alexa 488-conjugated anti-rabbit immunoglobulin sec-
ondary antibody (Molecular Probes, Leiden, Netherlands).
For all samples granulation, size, and ﬂuorescence intensity
were recorded on a FACStar + cell sorter (BD Biosciences,
San Jose, CA, USA) at 800cells/s, or on an Easycyte Plus
capillary cytometer (Guava Technologies, Hayward, CA,
USA) at a rate of 0.59μL/s. Data are expressed as mean
ﬂuorescence/cell; no cut oﬀ signal was applied.
2.9. TNF-α Secretion Assay. Human PBMCs from CD
patients were incubated in 24 well culture plates at
5·105 cells/mL for 24 hours at 37
◦C in a humidiﬁed
5% CO2/95% air atmosphere in presence of increasing
concentrations (ranging from 10
−7Mt o1 0
−5M) of original
somatostatin analogs, with or without activation by LPS
(5μg/mL). Compounds were dissolved in PBS. Plates were
centrifuged for 15 minutes at 200g (20
◦C) and supernatants
stored at −20
◦C, prior to cytokine determination as previ-
ously described [4].
2.10. Statistics. Real-time RT-PCR data were quantiﬁed
using the SDS 2.2.1 software package (Applied Biosystems).
Results were quantiﬁed in a relative comparative study, using
an automatic baseline and threshold to record the cycle
thresholds (Cts) setting and the 18S rRNA gene expression
as a reference for normalization (ΔCts). Student’s t-test was
used with a signiﬁcance threshold of P<. 05.
Data from ELISA have been expressed as a percentage of
the basal cytokine secretion or as means (± SE); “n”r e f e r st o
thenumberofexperiments.Resultswerecomparedusingthe
nonparametric Mann–Whitney U test. The level of statistical
signiﬁcance was ﬁxed at P<. 05.
3. Results
By monitoring non-orphan RCPGs (i.e., 279 among the
382 RCPGs tested) in PBMCs of 10 healthy donors and 10
CD patients, we found that the data obtained were highly
dependantonRNAintegrity.TheintegrityofRNAmolecules
is of paramount importance for experiments that try to
reﬂect the snapshot of gene expression at the moment of
RNA extraction. The RNA integrity number (RIN) is an
important tool regrettably often disregarded, in conducting
valid gene expression measurement experiments as real-time
PCRorDNAmicroarray[6].AfterRINdeterminationofour
20 samples, only 4 CD patients and 4 paired healthy donors
could be considered reliable due to sample degradation yet
withhandlingandshippingindryicefromthehospitaltothe
laboratory. Thus even with only 4 CD patients and 4 controls
but of reliable origins, we found that SSTR1 and 5 receptors
were found diﬀerentially expressed among the 279 identiﬁed4 Mediators of Inﬂammation
Table 1: Diﬀerential gene expression in (a) PBMCs of healthy donors and CD patients, (b) PBMCs of healthy donors and CD patients after
LPS stimulation and (c) biopsies experiments. Results from each card were quantiﬁed in a relative comparative study, using an automatic
baseline and threshold to record the cycle thresholds (Cts) setting and the 18S rRNA gene expression as a reference for normalization (ΔCts).
Identiﬁcation of genes diﬀerentially expressed in Crohn’s patients versus control group was performed (ΔΔCts) using standard statistical
analysis methods as the Student’s t-test with the commonly accepted signiﬁcance threshold of P<. 05.
(a)
Assay ID Gene Symbol Gene Name T-TEST Average ⊗⊗Ct
Hs00265647 s1 SSTR5 somatostatin receptor 5 0.038 9.6
Hs00171054 m1 CCR7 chemokine (C-C motif) receptor 7 0.16 -6.56
(b)
A s s a iI D G e n eS y m b o l G e n eN a m e T - T E S T A v e r a g e⊗⊗Ct
Hs00265647 s1 SSTR5 somatostatin receptor 5 0.39 1.80
(c)
A s s a yI D G e n eS y m b o l G e n eN a m e T - T E S T A v e r a g e⊗⊗Cts
Hs00171054 m1 CCR7 chemokine (C-C motif) receptor 7 0.03 3.36
Hs00265647 s1 SSTR5 somatostatin receptor 5 0.33 1.31
RCPGs. On the other hand, when we explored expression
proﬁles of biopsies obtained by endoscopies from ﬁve CD
patients, another pattern came out when we compared
biopsiesfrominﬂamedtonon-inﬂamedareas.Thistimeonly
one receptor (CCR7) showed a signiﬁcant overexpression in
inﬂamed areas.
3.1. Expression of SSTR5 mRNA and CCR7 in PBMCs of
CD Patients. A signiﬁcant increase in SSTR5 mRNA levels
(Table 1(a)) was observed in CD patients PBMCs: SSTR5 is
overexpressedmorethan417±71times(P<. 05).Activation
by LPS did not aﬀect SSTR5 expression in CD patients
(Table 1(b)). No diﬀerence in CCR7 mRNA expression was
found in CD PBMCs when compared to those from healthy
donors.
3.2. Correlation of mRNA Expression with Correspondent
Protein Synthesis in PBMCs. Flow cytometry experiments
were carried out on PBMCs to verify if protein expression
corresponds to such a dramatic mRNA overexpression. The
histogram in Figure 1 shows healthy PBMCs (B) with 70%
exhibiting positive staining for SSTR5. After LPS activation
100% of healthy controls’ PBMCs were presenting SSTR5
proteins. By contrast, in CD patients, all PBMCs showed
positive staining for SSTR5 independently of activation (D)
or not (C) by LPS. Nevertheless, the expected protein 400-
fold SSTR5 overexpression was never seen when comparing
healthy PBMCs (A) to CD patient’s PBMCs (C). From these
results, it appears that PBMCs from CD patients present
the SSTR5 expression level of LPS-activated PBMCs from
healthy donors, but no correlation could be found between
the rate of mRNA and protein expression.
Neither confocal microscopy, nor ﬂow or capillary
cytometry showed CCR7 overexpression by healthy controls
or CD patients PBMCs.
Table 2: Results of the DNA sequencing analysis of PBMCs for
SSTR5in4controldonorsand4CDpatients.mRNAextractionwas
realized from PBMC of 4 CD patients and 4 control donors. cDNA
was obtained after RT-PCR and PCR. Total cDNA was checked for
integrityandconcentrationusingtheDNA7500LabChipkitonthe
Agilent 2100 bioanalyzer and for purity by reading the absorbance
at 260 and 280 nm with ratios A260/A280 always between 1.8 and
2.0.
Donors Size (bp) Average size (bp) ± sd
Control 1 1284
1298 ±10 Control 2 1310
Control 3 1294
Control 4 1302
CD patient 1 1259
1263 ±4 CD patient 2 1259
CD patient 3 1266
CD patient 4 1266
3.3. Deletion of 35bp in DNA Sequence of SSTR5 in PBMCs
of CD Patients. The extraction of mRNA was realized for
PBMCs of 4 CD patients and 4 control donors. cDNA
was obtained from RT-PCR and PCR. We found that the
sequence of SSTR5 DNA in CD patients was diﬀerent from
control donors (Table 2). A smaller sequence in CD patients
is always observed with an average diﬀerence of 35bp. Thus
the hypothesis of a deletion can be proposed. This could give
a reason for CD patients to produce more SSTR5 proteins
than control donors in order to supply a constant binding of
somatostatin to the cells in case the protein is less eﬃcient in
ligand recognition.
3.4. Inhibition of the Proinﬂammatory Cytokine TNF-α by
Somatostatin Analogs in PBMCs from CD Patients. HavingMediators of Inﬂammation 5
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Figure 1: SSTR5 protein expression in PBMCs of CD patients and healthy donors activated or not by LPS. To mimic inﬂammation, PBMCs
were incubated in presence or absence of LPS (1μg/mL) for 2 hours 30 minutes at 37
◦C. The cells were ﬁxed and permeabilized and SSTR5
revealed by an Alexa 488 coupled antibody. The histogram (b) shows that after LPS activation of healthy PBMCs, all cells were presenting
SSTR5 proteins, in the same way that PBMCs from CD patients activated (d) or not (c) by LPS.
found that such a high SSTR5 mRNA overexpression does
not correlate to the SSTR5 protein levels in addition that CD
patients present a 35bp deletion in SSTR5 DNA, we intend
to assess if the expressed SSTR5 remains active in PBMCs
of CD patients. To do so, we tested the potency of diﬀerent
original somatostatin analogs to inhibit the production of
the proinﬂammatory cytokine TNF-α after LPS activation
of PBMCs obtained in CD patients (Figure 2). All four
tested analogues were found active, even if in diﬀerent rates,
emphasizing the eﬃciency of the SSTR present at the surface
of CD patients PBMCs.
3.5. Expression of CCR7 mRNA in Biopsies from CD Patients.
In biopsies of intestinal tissues of CD patients, CCR7 was
overexpressed by 10 ± 3 times compared to healthy donors
colonic mucosa (Table 1(c)). Somatostatin receptor 5 mRNA
expression was not increased in control or CD patient’s
intestinal mucosa.6 Mediators of Inﬂammation
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Figure 2: Inﬂammatory response (TNF-α secretion) of CD
patient’s PBMCs in presence of somatostatin analogs. CD patients
PBMCs (5·105 cells/mL) were activated by LPS for 24 hours in
presence of increasing doses of somatostatin analogs (10
−7 Mt o
10
−5 M). Quantitative evaluation of the secreted cytokine TNF-
α was done by sandwich ELISA as described in Materials and
Methods.
3.6. Localization of CCR7 and SSTR5 in Tissues of CD
Patient. Immunoﬂuorescence detection of CCR7 was not
possible by classical epiﬂuorescence techniques due to the
high autoﬂuorescence of the mucus and secretions of the
intestinal tissues. It is only by confocal microscopy with an
Alexa 647 labeled secondary antibody that we were able to
detect CCR7 expression in the inﬂamed CD tissues versus
non-inﬂamed part. Moreover, the images obtained show
that the detected receptors were located at cell membrane,
especially on the surface of mononuclear cells present in the
intestinal lamina propria (Figure 3).
Asexpected,noSSTR5labelingcouldbefoundinhealthy
controls or CD patients’ colon biopsies, in agreement with
theresultsobtainedearlierinrealtimeRT-PCRexperiments.
4. Discussion
The present work highlights through two precise examples,
the importance of RNA quality assessment in data interpre-
tation in particular that of the RNA Integrity Number (RIN)
to assign integrity values to RNA. Establishment of RIN,
a step often mishandled, obviously could not be replaced
by examining a high number of samples. In addition, our
results illustrate the fact that ﬂow cytometry and confocal
microscopy, in combination with (a) cellular challenge(s)
(i.e. response to LPS activation) constitute important tools
which could bring new highlights to results obtained by
molecular biology experiments.
We found a signiﬁcant increase in SSTR5 mRNA levels
(more than 400 times) in inactive CD patients PBMCs. By
contrast, ﬂow cytometry experiments showed that SSTR5
protein expression did not reveal a protein expression levels
corresponding to such a dramatic mRNA overexpression.
The proﬁle of SSTR5 protein expression in inactive CD
patients’ PBMCs that we observed in basal conditions
(i.e., without any in vitro exogenous activation of PBMCs)
was comparable to the SSTR5 expression of LPS-activated
PBMCs from healthy donors. Furthermore, to answer the
question of the functional activity of SSTRs from inactive
CD patients, we assessed the ability of diﬀerent somatostatin
analogs to inhibit PBMCs TNF-α in vitro production. All
four tested original analogues were found to be active as
theysigniﬁcantlyinhibitTNF-αsecretion,demonstratingthe
eﬃciency of the SSTR present at the surface of CD patients
PBMCs to adequately fulﬁll this biological property but not
explaining why SSTR5 mRNA is overexpressed.
One hypothesis to explain such lack of correlation
between the 400-fold increase in SSTR5 mRNA levels
and the smaller increase in SSTR5 protein expression in
CD patients PBMCs concerns the internalization and up-
regulation of SSTR5 [8]. The cytoplasmic tail of SSTR5
is crucial for interacting with adenylyl cyclase and so in
mediating desensitization and internalization [9]. Using
BLAST (http://blast.ncbi.nlm.nih.gov/), we identiﬁed spe-
ciﬁc primers to amplify a locus inside the exon number 2
of SSTR5 after the promoter region. The deletion of 35bp
after ampliﬁcation by PCR suggests an implication of the
SSTR5 coding sequence (CDS) in CD patients. The presence
of a deletion of the C-terminal tail of the GPCR may aﬀect
recycling of this GPCR by internalization and up-regulation.
Thus the binding between SSTR5 and somatostatin will
not be able to activate the adenylyl cyclase; as a result this
may lead to favor increase in SSTR5 mRNA expression as
a result of the absence of a negative retroactive regulatory
loop. However, as we have shown that synthetic somatostatin
analogs are still able to down regulate the TNF-α production
ofPBMCsofCDpatientsafterLPSactivation,thishypothesis
remains questionable and needs additional work, both to
verify if the lacking 35bp are located in the C-terminal
region, and to identify the SSTR receptor(s) involved in the
inhibition ofPBMCsTNF-αproductionbytheusedsomato-
statinanalogues,asotherSSTRreceptorsthanSSTR5maybe
involved or may compensate an hypothetical dysfunction of
SSTR5.
Although it was not the aim of the present study, such an
increase of SSTR5 mRNA and protein expression in PBMCs
from clinically inactive CD patients, compared to healthy
controls, remains intriguing. Actually, somatostatin has been
shown in several studies to participate in inﬂammatory and
immune response [10]. This role has been largely supported
by the presence of somatostatin and SSTRs in cells of
inﬂamed organs [11], structures of the immune system such
as human lymphoid tissues, and ﬁnally peripheral blood
cells [10]. The biological activity of somatostatin is generally
of inhibitory nature. Five somatostatin receptor subtypes,
termed SSTR (1–5), have been cloned so far from human
tissues. SSTR (1–5) are encoded by ﬁve non-allelic genes
on chromosomes 14, 17, 22, 20, and 16, respectively [12–
15]. Somatostatin and somatotropin release-inhibiting fac-
tors (SRIF) are cyclopeptides. Somatostatin is produced byMediators of Inﬂammation 7
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Figure 3: CCR7 presence in the lamina propria of inﬂamed tissues of CD patients (c’) compared to the healthy donor (c) by confocal
microscopy. (a) Hematoxylin/eosin coloration of healthy intestine showing the localization of the diﬀerent magniﬁcations. (b and b’)
Magniﬁcation of the Lieberkuhn’s glands to show localization of the chorion: (b) non-inﬂamed tissue, (b’) inﬂamed part. (c and c’) CCR7 is
detected in the inﬂamed CD tissues by confocal microscopy revealed by an Alexa 647 labeled secondary antibody: (c) non-inﬂamed lamina
propria, (c’) inﬂamed lamina propria. CCR7 staining (B and B’), nucleus staining with DAPI (A and A’), green autoﬂuorescence (C and C’)
and corresponding merged images (D and D’).
normal endocrine, gastrointestinal, immune, and neuronal
cells, as well as by certain tumors [16–20]. The highly potent
somatostatin peptides SRIF-14 and SRIF-28 are generated as
C-terminal products from prosomatostatin. By binding to
their receptors on target cells, SRIFs act as potent inhibitors
of various secretory processes and cell proliferation [16–
20]. Previous studies have demonstrated the presence of
SSTRs in inﬂammation [21–25]. It is widely accepted that
the neuropeptide somatostatin is an important regulator
of the immune system in a number of tissues. There is
abundance of data showing that inﬂammatory cytokines
regulate somatostatin in immune and neural cells [26–29],
and it would be interesting to explore more accurately the
mechanism(s) involved and the potential role of SSTRs, for
example, SSTR5 as anti-inﬂammatory therapeutic targets.
In addition, high SSTR5 expression in PBMCs from CD8 Mediators of Inﬂammation
showing no clinical or biological signs of activity could
suggest that this SSTR5 overexpression may potentially be
considered as a biomarker of CD. However, this has to be
conﬁrmed in a larger patients population, homogeneous
both for disease activity and patients treatments; this work
is currently ongoing.
On the other hand, and as a second example, we studied
CCR7 mRNA and protein expression in mucosal biopsies of
intestinal tissues of CD patients. We found CCR7 mRNA
expression to be 10-times increased compared to healthy
controls colonic mucosa. This time corresponding CCR7
protein expression was detected in the inﬂamed CD tissues
versus non-inﬂamed.
Chemokines also represent important actors in the
control of inﬂammatory response. They aﬀect cells by
binding and activating surface receptors that are seven trans-
membrane domains GPCR. Chemokines are up regulated
in inﬂammatory conditions and are produced by activated
leukocytes and tissue cells as well as numerous tumors.
They control the recruitment of eﬀector leukocytes and
thus, determine the composition of inﬂammatory inﬁltrates
[30]. In this study we observed increased CCR7 mRNA
expressionininﬂamedCDcolonicmucosa,aswellasaCCR7
staining in lamina propria mononuclear cells. These results
are in accordance with data reported by Middel et al.[ 31]
suggesting that in CD, lymphoid chemokines CCL20 (and
its receptor CCR6) as well as CCL19 and CCL21 (and their
receptor CCR7) may lead to an increased number of mature
dendritic cells (DC) in the aﬀected bowel wall, leading to
local activation and proliferation of T cells, the formation of
DC/T cell clusters expressing CCR7, and ﬁnally participating
in the maintenance of the intestinal inﬂammatory and
immune response. Such a “sequestration” of CCR7-positive
immune cells could explain why we did not ﬁnd increased
CCR7 expression in PBMCs from CD patients. Whether the
modulation of the lymphoid chemokines or of their recep-
tors might represent a potent and safe therapeutic strategy
remains to be clariﬁed. If CCR7 is overexpressed in inﬂamed
bowel of CD patients, SSTR5, an important factor in down
regulating the immune response, was equally expected in
the same tissue. Absence of SSTR5 in the inﬂamed tissue of
CD patients can explain why the somatostatinergic system
is not playing its immunosuppressive role in the bowel. Our
data suggest that there is no need to develop new analogs
of somatostatin if there is such an important lack of target
expression in the inﬂamed bowel of CD patients.
For CD patients, we observed a diﬀerence for SSTR5
mRNAexpression in circulating blood comparedto biopsies.
Such a diﬀerence for two distinctive localizations is diﬃcult
to explain. The high presence of SSTR5 mRNA in PBMC of
CDpatientscouldbeaconsequenceofadiminishedimmune
response, in turn leading to uncontrolled accumulation of
the inducer stimuli thus activating the adaptive immune
system [32]. We followed in parallel the expression of a
panel of genes implicated in the inﬂammatory process.
Only a slight over-expression of biomarkers like CHRM1,
CCR10, FY, BDKRB1, and HTR1B (data not shown) was
observed. For the over-expression of CCR7 in biopsies of CD
patients, this phenomenon can be due, directly or indirectly,
to a genetic defect inducing an exaggerated innate response
to the intestinal microbial ﬂora, leading to an excessive
inﬂammatory response [33].
In conclusion, the present study highlights the need to be
cautious in interpreting data only providing information on
RNA expression or protein expression, in order to avoid false
interpretation on receptor expression and false physiological
or pathological relevance. These results emphasize also the
importance of RNA quality in data analyses, in particular
when using high throughput techniques like DNA chips
or micro-ﬂuidic devices. Finally, and despite it has not
been the purpose of the study, we present preliminary
results suggesting a role for SSTR5 and CCR7 in CD
pathogenesis, which might if conﬁrmed in further large scale
studies, conduct to identify (a) new disease marker(s) and/or
therapeutic target(s).
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